



HAL
open science

Idiopathic Recurrent Pericarditis: Not Really So Idiopathic?

François Roubille, Clément Delmas, Camille Roubille

► **To cite this version:**

François Roubille, Clément Delmas, Camille Roubille. Idiopathic Recurrent Pericarditis: Not Really So Idiopathic?. *Journal of the American Heart Association*, 2022, 11 (11), 10.1161/JAHA.122.026218 . hal-03690012

HAL Id: hal-03690012

<https://hal.science/hal-03690012>

Submitted on 8 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Idiopathic Recurrent Pericarditis: Not Really So Idiopathic?

François Roubille MD, PhD; Clément Delmas MD, PhD; Camille Roubille, MD, PhD

In this issue of the *Journal of the American Heart Association (JAHA)*, Peet¹ challenges the current concept of idiopathic recurrent pericarditis (IRP). Indeed, “idiopathic” means “arising spontaneously or from an obscure or unknown cause,” which implies that the pathophysiology is not established, and the treatment should remain empirical. In 2 words, behind this learned word, we hide our ignorance.

By contrast, the authors propose herein that IRP may be largely driven by the well-known interleukin-1 pathway. Given that interleukin-1 is well established as a key actor in many cardiovascular disorders, this new approach seems promising, especially because targeting interleukin-1 β has already been demonstrated to be a potential means to struggle coronary disease,² in large-scale trials. The concept has been shown to be applicable for the first time in the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study).³ Similarly, the 2 international large studies of colchicine in patients with coronary artery disease, LoDoCo2 (Low-Dose Colchicine 2)⁴ in stable coronary artery disease and COLCOT (Colchicine Cardiovascular Outcome Trial)⁵ in recent myocardial infarction, have shown a benefit of low-dose colchicine (0.5 mg per day). More important, colchicine has been shown to be safe too in these 2 studies recruiting >10 000 patients, followed up for

>2 years. From a pathophysiological and pharmacological point of view, because colchicine targets at least in part interleukin-1 β ,^{6,7} all of these considerations pave the way for the use of long-term strategies targeting interleukin-1 β in various cardiovascular diseases.

Furthermore, more specifically in the field of pericarditis, colchicine is also the cornerstone for the prevention of recurrent episodes, as was demonstrated almost 2 decades ago.^{8,9} More recently, drugs targeting interleukin-1 β more directly have been shown of interest: riloncept and [anakinra](#) (Figure).

In the AIRTRIP (Anakinra-Treatment of Recurrent Idiopathic Pericarditis) trial,¹⁰ anakinra, an interleukin-1 β recombinant receptor antagonist, reduced the risk of recurrence over a median of 14 months in a small population of patients with recurrent pericarditis (with ≥ 3 previous recurrences), elevation of CRP (C-reactive protein), colchicine resistance, and corticosteroid dependence (n=11 receiving anakinra, and n=10 receiving placebo).

Riloncept is a soluble decoy receptor “trap,” binding both interleukin-1 α and interleukin-1 β . In the RHAPSODY (Riloncept Inhibition of Interleukin-1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study) trial,¹¹ patients with recurrent pericarditis have been randomized to receive either riloncept or placebo. On riloncept, they presented nearly no recurrence at 12 months (n=31 receiving riloncept versus n=30 receiving placebo).

Key Words: Editorials ■ autoinflammation ■ idiopathic ■ interleukin-1 ■ pericarditis ■ recurrence

The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

Correspondence to: François Roubille, MD, PhD, Cardiology Department, INI-CRT, PhyMedExp, INSERM, CNRS, CHU de Montpellier, Université de Montpellier, Montpellier, France. Email: f-roubille@chu-montpellier.fr




Figure. Main studies discussed in the article, presented shortly.

We could obtain about 50% reduction of recurrences when targeting one of the first recurrences with a pleiotropic anti-inflammatory agent, such as colchicine. By contrast, a deeper reduction (about 80%) is observed when targeting highly recurrent forms with a specific anti-interleukin-1 β anti-inflammatory agent. AIRTRIP indicates Anakinra-Treatment of Recurrent Idiopathic Pericarditis; CORE, COLchicine for REcurrent Pericarditis; and CORP, Colchicine for Recurrent Pericarditis.

In these 2 studies, safety was particularly good. One major limitation is the small size of the included populations, but this is often the case for this rare clinical setting. Because the uptake of evidence-based therapies

remains limited, corroborating the involvement of interleukin-1 β in pathophysiology of IRP remains mandatory. Herein, the authors studied in depth their cohort of 136 patients with IRP and 1910 patients with rare monogenic

interleukin-1–mediated systemic autoinflammatory diseases. This is a fairly large population, representing a larger population than the 2 studies cited above combined, and the largest published IRP cohort with detailed clinical features. That is the reason why, although this is an observational cohort with its well-known biases, the authors consider herein a longer follow-up and a real-life population, so that this approach appears complementary to the randomized trials.

Consistent with the available literature, patients with IRP show excellent responses to colchicine and anti-interleukin-1 drugs, suggesting common mechanisms and providing a paradigm for the approach to IRP treatment. Interestingly, the authors underline the potential adverse effects of corticosteroids, which would increase chronic symptoms after the acute phase. This consideration, which is not so new, prompts a better understanding of the underlying pathophysiology.

Herein, the authors propose a comprehensive genetic analysis in IRP of the coding regions of the 4 genes known to cause interleukin-1–mediated inflammation. They confirm that IRP is a feature of each of the 4 monogenic interleukin-1–mediated autoinflammatory diseases. They even show that certain mutations may play a role in IRP, suggesting autoinflammation as a disease mechanism. All these results taken into consideration, pericarditis could now be considered at least partly related to an autoinflammatory process, and IRP appears to be a new manifestation of autoinflammation. This is important not only from a pathophysiological point of view, but also from a therapeutic approach.

Indeed, the autoinflammatory process implies an early and adequate therapy to fight against the vicious circle, but also paves the way for targeted therapies, as in other clinical settings, such as the canakinumab, another anti-interleukin-1 β biotherapy, dedicated to rare autoinflammatory diseases. Specific and targeted management, or step-by-step management, could then be tailored, particularly on the basis of pharmacological and pharmacogenomic approaches, depending on genetic analysis.

As highlighted in [the Figure](#), targeting inflammation through a pleiotropic anti-inflammatory drug, such as colchicine, offers a reduction of about 50% of recurrences. By comparison, in the highly recurrent forms, where autoinflammatory process linked to the interleukin-1 β pathway is suggested, the size of effect on frequent recurrences is even larger.

Finally, this article is hypothesis generating, suggesting a new way of considering pericarditis. New actors could also be taken into considerations, including the COVID-19 or other viruses, that could interfere with autoimmunity.

Prospective studies of both acute and recurrent pericarditis are much needed.

ARTICLE INFORMATION

Affiliations

Cardiology Department, INI-CRT, PhyMedExp, INSERM, CNRS, CHU de Montpellier, Université de Montpellier, France (F.R.); Intensive Cardiac Care Unit, Rangueil University Hospital/Institute of Metabolic and Cardiovascular Diseases, UMR-1048, National Institute of Health and Medical Research, Toulouse, France (C.D.); and Department of Internal Medicine, PhyMedExp, CHU Montpellier, Montpellier University, Montpellier, France (C.R.).

Disclosures

None.

REFERENCES

1. Peet CJ, Rowczenio D, Omoyinmi E, Papadopoulou C, Mapalo BRR, Wood MR, Capon F, Lachmann HJ. Pericarditis and autoinflammation: a clinical and genetic analysis of patients with idiopathic recurrent pericarditis and monogenic systemic autoinflammatory diseases at a national referral center. *J Am Heart Assoc.* 2022;11:e024931. doi: [10.1161/JAHA.121.024931](#)
2. Roubille F, Tardif JC. Inflammation and the heart—prime time for new therapeutic approaches. *Expert Opin Emerg Drugs.* 2013;18:259–261. doi: [10.1517/14728214.2013.811487](#)
3. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med.* 2017;377:1119–1131. doi: [10.1056/NEJMoa1707914](#)
4. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu X-F, Ireland MA, Lenderink T, et al. Colchicine in patients with chronic coronary disease. *N Engl J Med.* 2020;383:1838–1847. doi: [10.1056/NEJMoa2021372](#)
5. Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. *N Engl J Med.* 2019;381:2497–2505. doi: [10.1056/NEJMoa1912388](#)
6. Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC. Colchicine: an old wine in a new bottle? *Antiinflamm Antiallergy Agents Med Chem.* 2013;12:14–23. doi: [10.2174/1871523011312010004](#)
7. Roubille F, Tardif JC. Colchicine for secondary cardiovascular prevention in coronary disease. *Circulation.* 2020;142:1901–1904. doi: [10.1161/CIRCULATIONAHA.120.051240](#)
8. Imazio M, Belli R, Brucato A, Cemin R, Ferrua S, Beqaraj F, Demarie D, Ferro S, Forno D, Maestroni S, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. *Lancet.* 2014;383:2232–2237. doi: [10.1016/S0140-6736\(13\)62709-9](#)
9. Imazio M, Brucato A, Cemin R, Ferrua S, Belli R, Maestroni S, Trincherio R, Spodick DH, Adler Y, Investigators C. Colchicine for recurrent pericarditis (CORP): a randomized trial. *Ann Intern Med.* 2011;155:409–414. doi: [10.7326/0003-4819-155-7-201110040-00359](#)
10. Brucato A, Imazio M, Gattorno M, Lazaros G, Maestroni S, Carraro M, Finetti M, Cumetti D, Carobbio A, Ruperto N, et al. Effect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: the AIRTRIP randomized clinical trial. *JAMA.* 2016;316:1906–1912. doi: [10.1001/jama.2016.15826](#)
11. Klein AL, Imazio M, Cremer P, Brucato A, Abbate A, Fang F, Insalaco A, LeWinter M, Lewis BS, Lin D, et al. Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis. *N Engl J Med.* 2021;384:31–41. doi: [10.1056/NEJMoa2027892](#)
12. Peet CJ, Rowczenio D, Omoyinmi E, Papadopoulou C, Mapalo BRR, Wood MR, Capon F, Lachmann HJ. Pericarditis and autoinflammation: a clinical and genetic analysis of patients with idiopathic recurrent pericarditis and monogenic systemic autoinflammatory diseases at a national referral center. *J Am Heart Assoc.* 2022;11:e024931. doi: [10.1161/JAHA.121.024931](#)